Literature DB >> 24997571

Burden of cardiovascular disease in chronic obstructive pulmonary disease.

Shikhar Agarwal1, Haala Rokadia2, Todd Senn1, Venu Menon3.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) and atherosclerotic vascular disease share several etiopathogenic factors.
PURPOSE: To compare the prevalence of self-reported cardiovascular and cerebrovascular disease (CCVD) between COPD and non-COPD subjects using the National Health and Nutrition Examination Survey (NHANES) database. Among subjects without pre-existent CCVD, the short-term and lifetime risks of future CCVD were also compared between the two groups.
METHODS: Pooled NHANES 2007-2010 data were analyzed in May 2012 and April 2013. Based on predicted Framingham risk, subjects without self-reported CCVD were classified as follows: high short-term risk, low short-term/high lifetime risk, and low short-term/low lifetime risk for future CCVD.
RESULTS: Estimated self-reported CCVD prevalence was 20.0% and 7.4% in COPD and non-COPD groups, respectively (p<0.001). On multivariable analysis, COPD was an independent risk factor for prevalent self-reported CCVD (prevalence ratio=1.4, 95% CI=1.1, 1.8). Among subjects without CCVD, there were significant differences in predicted future CCVD risk between the two groups. In the non-COPD group, prevalence of high short-term risk, low short-term/high lifetime risk, and low short-term/low lifetime risk was 18.9%, 62.7%, and 18.4%, respectively. In the COPD group, corresponding prevalence estimates were 35.8%, 53.2%, and 11.1%, respectively. Men and women had significantly different risk factor profiles for future CCVD.
CONCLUSIONS: The prevalence of self-reported CCVD was significantly higher in subjects with COPD than in those without COPD. Among subjects without pre-existent CCVD, the risk of future CCVD was significantly higher in the COPD group than in the non-COPD group.
Copyright © 2014 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24997571     DOI: 10.1016/j.amepre.2014.03.014

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  5 in total

1.  Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Haiquan Huang; Georges Nakhoul; Stacey E Jolly; Susana Arrigain; Raed A Dweik; Joseph V Nally
Journal:  Am J Nephrol       Date:  2016-02-19       Impact factor: 3.754

2.  Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.

Authors:  Gunnar Gudmundsson; Olof Birna Margretardottir; Martin Ingi Sigurdsson; Tamara B Harris; Lenore J Launer; Sigurdur Sigurdsson; Orn Olafsson; Thor Aspelund; Vilmundur Gudnason
Journal:  Atherosclerosis       Date:  2016-07-28       Impact factor: 5.162

3.  GDF-15 plasma levels in chronic obstructive pulmonary disease are associated with subclinical coronary artery disease.

Authors:  Carlos H Martinez; Christine M Freeman; Joshua D Nelson; Susan Murray; Xin Wang; Matthew J Budoff; Mark T Dransfield; John E Hokanson; Ella A Kazerooni; Gregory L Kinney; Elizabeth A Regan; J Michael Wells; Fernando J Martinez; MeiLan K Han; Jeffrey L Curtis
Journal:  Respir Res       Date:  2017-02-28

4.  Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2).

Authors:  Vijay Kunadian; Danny Chan; Hani Ali; Nina Wilkinson; Nicola Howe; Elaine McColl; Jared Thornton; Alexander von Wilamowitz-Moellendorff; Eva-Maria Holstein; Graham Burns; Andrew Fisher; Deborah Stocken; Anthony De Soyza
Journal:  BMJ Open       Date:  2018-05-26       Impact factor: 2.692

5.  Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

Authors:  Nicola C Day; Subramanya Kumar; Gerard Criner; Mark Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Morrys C Kaisermann; Sally Kilbride; Peter Lange; David A Lomas; Neil Martin; Fernando J Martinez; Dave Singh; Robert Wise; David A Lipson
Journal:  Respir Res       Date:  2020-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.